BARCLAYS PLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2021$14,000
-54.8%
4,267
-46.6%
0.00%
Q2 2021$31,000
-68.4%
7,988
-68.7%
0.00%
Q1 2021$98,000
+151.3%
25,500
+193.4%
0.00%
Q4 2020$39,000
-82.4%
8,690
-33.6%
0.00%
Q3 2020$221,000
+34.8%
13,080
-10.8%
0.00%
Q2 2020$164,00014,667
+488800.0%
0.00%
Q4 2019$03
+200.0%
0.00%
Q1 2018$010.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2021
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 241,500$1,093,0000.17%
OCCUDO QUANTITATIVE STRATEGIES LP 90,584$410,0000.13%
EPIQ PARTNERS, LLC 10,550$48,0000.03%
Phoenix Holdings Ltd. 173,683$799,0000.02%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 5,500$25,0000.02%
CFO4Life Group, LLC 12,003$54,0000.02%
HighPoint Advisor Group LLC 15,733$115,0000.01%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 357,761$1,619,0000.01%
Virtu Financial LLC 24,484$111,0000.01%
ETF MANAGERS GROUP, LLC 93,902$435,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders